Omega‐3 and aspirin in the nonsurgical treatment of grade C periodontitis: A randomized clinical trial
Journal of Periodontology · 2025
DOI: 10.1002/jper.24-0322 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Journal of Periodontology, 2025. Verfasst von Cássia F Araujo und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diagnosis and Surgery, Division of Periodontology, Institute of Science and Technology, São Paulo State University, São José dos Campos…. Hauptthemen laut MEDLINE: Aspirin, Periodontitis, Fatty Acids, Omega-3, Anti-Inflammatory Agents, Non-Steroidal. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 49 Literaturangaben. Gefördert von: São Paulo Research Foundation, Fundação de Amparo à Pesquisa do Estado de São Paulo.
Abstract (Originalsprache)
Background
The use of omega‐3 (Ω‐3) polyunsaturated fatty acids and acetylsalicylic acid (ASA, aspirin) has shown better clinical outcomes in the treatment of periodontitis compared to nonsurgical periodontal therapy (NSPT) alone. This randomized clinical trial aimed to evaluate the use of 900 mg Ω‐3 and 100 mg ASA for 180 days as adjuncts to NSPT for generalized stage III–IV grade C periodontitis (GCP).
Methods
Patients underwent subgingival debridement (SD) associated with Ω‐3+ASA or cellulose placebo and received monthly prophylaxis. Clinical and immunological parameters were compared at baseline, 3, and 6 months after treatment. The daily dose of Ω‐3 consisted of 540 mg eicosapentaenoic acid (EPA) and 360 mg docosahexaenoic acid (DHA).
Results
Thirty‐eight patients, 12 males (7 in the SD+Ω‐3+AAS group and 5 in the SD+Placebo group; p > 0.05), with a mean age of 32.84 ± 5.47 and 30.42 ± 5.79 years, respectively ( p > 0.05), were included. Both groups showed significant improvements ( p < 0.05) in all full‐mouth parameters. Reductions in the number of pockets, mean probing depth (PD), and clinical attachment level of moderate and deep sites, as well as the number and percentage of residual pockets, were observed (intragroup p < 0.05; intergroup p > 0.05). However, residual pockets' mean PD decrease ( p < 0.05) was only observed at 6 months in the SD+Ω‐3+ASA group. The concentration of interleukin (IL)‐1β from moderate and deep pockets decreased ( p < 0.05) in both groups. The matrix metalloproteinase (MMP)‐9 to tissue metalloproteinase inhibitor (TIMP)‐1 ratio in the SD+Placebo group at 3 months revealed a proinflammatory profile in moderate (intergroup p = 0.006) and deep pockets (intergroup p < 0.001).
Conclusion
Ω‐3+ASA therapy did not add clinical benefits to the NSPT for generalized stage III–IV GCP, although some immunomodulatory benefits could be observed. Plain Language Summary The use of omega‐3 (Ω‐3) and aspirin (ASA) along with subgingival debridement (SD) for root decontamination of periodontal pockets has shown better results in the nonsurgical treatment of gum disease and bone loss compared to SD alone. This investigation aimed to evaluate the use of 900 mg Ω‐3 and 100 mg ASA for 180 days as adjuncts to the treatment of patients with gum disease and rapid bone loss rate. Thirty‐eight patients underwent SD associated with Ω‐3+ASA or placebo. Clinical and immunological parameters were evaluated at the beginning of the study and 3 and 6 months after. Both groups showed significant improvements. A significant reduction in the number of sites with diseased pockets was observed. The number of residual diseased sites was also significantly reduced, without differences between the groups. However, a significant decrease in the pocket size of the diseased sites was only observed at 6 months in the group that received Ω‐3+ASA. The concentration of interleukin (IL)‐1β (a protein present in the inflammatory process) from diseased sites significantly decreased in both groups. We concluded that the proposed therapy did not add any significant clinical benefits for patients with gum disease and rapid bone loss rate.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Diagnosis and Surgery, Division of Periodontology, Institute of Science and Technology, São Paulo State University, São José dos Campos, São Paulo, Brazil.
- Division of Dentistry, Faculdade Santo Antônio, Caçapava, São Paulo, Brazil.
- Dental Research Division, Guarulhos University, Guarulhos, São Paulo, Brazil.
- Department of Oral Health Practice, College of Dentistry, University of Kentucky, Lexington, Kentucky, USA.
- Department of Periodontics and Prosthodontics, Division of Periodontics, Piracicaba Dental School, University of Campinas, Piracicaba, São Paulo, Brazil.
ORCID-Profile: Cássia F Araujo, Naira M R B Andere, Nidia C Castro Dos Santos, Laís F F Ferraz, Manuela M V Miguel, Ingrid F Mathias-Santamaria, Mabelle F Monteiro, Luciana M Shaddox, Renato C V Casarin, Mauro P Santamaria
Förderung
- São Paulo Research Foundation
- Fundação de Amparo à Pesquisa do Estado de São Paulo
Zitieren
APA
Araujo, C. F., Andere, N. M. R. B., Castro Dos Santos, N. C., Ferraz, L. F. F., Miguel, M. M. V., Mathias-Santamaria, I. F., Monteiro, M. F., Shaddox, L. M., Casarin, R. C. V., & Santamaria, M. P. (2025). Omega‐3 and aspirin in the nonsurgical treatment of grade C periodontitis: A randomized clinical trial. Journal of Periodontology. https://doi.org/10.1002/jper.24-0322
Vancouver
Araujo CF, Andere NMRB, Castro Dos Santos NC, Ferraz LFF, Miguel MMV, Mathias-Santamaria IF, et al. Omega‐3 and aspirin in the nonsurgical treatment of grade C periodontitis: A randomized clinical trial. Journal of Periodontology. 2025. doi:10.1002/jper.24-0322
BibTeX
@article{Araujo2025,
author = {Araujo, Cássia F and Andere, Naira M R B and Castro Dos Santos, Nidia C and Ferraz, Laís F F and Miguel, Manuela M V and Mathias-Santamaria, Ingrid F and Monteiro, Mabelle F and Shaddox, Luciana M and Casarin, Renato C V and Santamaria, Mauro P},
title = {Omega‐3 and aspirin in the nonsurgical treatment of grade C periodontitis: A randomized clinical trial},
journal = {Journal of Periodontology},
year = {2025},
doi = {10.1002/jper.24-0322}
}
EUVIMED